Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Medigene AG

< Previous 1 2 Next >
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
From Medigene AG
Via GlobeNewswire
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
From Medigene AG
Via GlobeNewswire
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
From Medigene AG
Via GlobeNewswire
Medigene to Present at Upcoming Conferences
From Medigene AG
Via GlobeNewswire
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
From Medigene AG
Via GlobeNewswire
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
From Medigene AG
Via GlobeNewswire
Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
From Medigene AG
Via GlobeNewswire
Medigene to Present at Upcoming Scientific Conferences
From Medigene AG
Via GlobeNewswire
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
From Medigene AG
Via GlobeNewswire
Medigene AG Secures European Patent for its iM-TCR Technology
From Medigene AG
Via GlobeNewswire
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
From Medigene AG
Via GlobeNewswire
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
From Medigene AG
Via GlobeNewswire
Medigene AG to report full year 2023 financial results on March 28, 2024
From Medigene AG
Via GlobeNewswire
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting
From Medigene AG
Via GlobeNewswire
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo
From Medigene AG
Via GlobeNewswire
Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies
From Medigene AG
Via GlobeNewswire
Medigene to Present at Upcoming Conferences
From Medigene AG
Via GlobeNewswire
Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors
From Medigene AG
Via GlobeNewswire
Medigene AG to attend at the 42nd Annual J.P. Morgan Healthcare Conference
From Medigene AG
Via GlobeNewswire
Medigene AG Announces Prioritization of Pipeline and Resource Allocation as well as Extension of Cash Runway
From Medigene AG
Via GlobeNewswire
Medigene amends 2023 financial guidance
From Medigene AG
Via GlobeNewswire
Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating capability of its proprietary E2E Platform to generate multiple enhanced TCR-T therapies against mKRAS G12V A*11
From Medigene AG
Via GlobeNewswire
Medigene Reports Financial Results and Corporate Update for Q3 2023
From Medigene AG
Via GlobeNewswire
Medigene presents first pre-clinical data of optimal affinity TCR targeting mKRAS G12V combined with a PD1-41BB costimulatory switch protein showing enhanced and sustained tumor killing
From Medigene AG
Via GlobeNewswire
Medigene to present new pre-clinical data for pipeline TCR-T therapies at the ESMO Congress 2023
From Medigene AG
Via GlobeNewswire
Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein
From Medigene AG
Via GlobeNewswire
Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library
From Medigene AG
Via GlobeNewswire
Medigene AG to present at the Baader Investment Conference 2023
From Medigene AG
Via GlobeNewswire
Medigene AG to present at the H.C. Wainwright 25th Annual Global Investment Conference
From Medigene AG
Via GlobeNewswire
Medigene presents rationale for combining its 3S TCRs with enhancement tools as an approach to improve clinical outcomes
From Medigene AG
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.